Tim is a partner in Goodwin’s Technology and Life Sciences groups, based in the Cambridge and London offices.
Mr. Worden regularly advises life sciences companies on licensing and partnering deals, R&D agreements, clinical trials agreements, distribution agreements, and a broad spectrum of regulatory matters. His expertise also includes advising on the IP and regulatory aspects of M&A transactions, IPOs and venture capital investments. Outside of the life sciences sector, Mr. Worden advises technology companies on their technology licensing and commercial agreements.
Mr. Worden’s life sciences regulatory expertise includes advising on a broad range of medicinal product and medical device regulatory issues. He also carries out regulatory investigations for clients in the sector, and assists clients with regulatory due diligence in connection with transactions.
Prior to joining Goodwin, he was a partner and co-head of the International Life Sciences Group at Taylor Wessing LLP. Mr. Worden was previously Legal Counsel and Company Secretary at Eli Lilly and Company Limited in the UK. He has a degree in Natural Sciences (Chemistry) from Cambridge University.